|
|
Background We conducted subanalyses of the combined results of the Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize the efficacy and safety of maraviroc in key subgroups of patients.
Methods We analyzed pooled data from week 48 from the two studies according to sex, race or ethnic group, clade, CC chemokine receptor 5 (CCR5) delta32 genotype, viral load at the time of screening, the use or nonuse of enfuvirtide in optimized background therapy (OBT), the baseline CD4 cell count, the number of active antiretroviral drugs coadministered, the first use of selected background agents, and tropism at baseline. Changes in viral tropism and the CD4 count at treatment failure were evaluated. Data on aminotransferase levels in patients coinfected with hepatitis B virus (HBV) or hepatitis C virus (HCV) were also analyzed.
Results A treatment benefit of maraviroc plus OBT over placebo plus OBT was shown in all subgroups, including patients with a low CD4 cell count at baseline, those with a high viral load at screening, and those who had not received active agents in OBT. Analyses of the virologic response according to the first use of selected background drugs showed the additional benefit of adding a potent new drug to maraviroc at the initiation of maraviroc therapy. More patients in whom maraviroc failed had a virus binding to the CXC chemokine receptor 4 (CXCR4) at failure, but there was no evidence of a decrease in the CD4 cell count at failure in such patients as compared with those in whom placebo failed. Subanalyses involving patients coinfected with HBV or HCV revealed no evidence of excess hepatotoxic effects as compared with baseline.
Conclusions Subanalyses of pooled data from week 48 indicate that maraviroc provides a valuable treatment option for a wide spectrum of patients with R5 HIV-1 infection who have been treated previously. (ClinicalTrials.gov numbers, NCT00098306
[ClinicalTrials.gov]
and NCT00098722
[ClinicalTrials.gov]
.)
Source Information
From the Universitätsklinik Köln, Cologne, Germany (G.F.); Chelsea and Westminster Hospital, London (M.N.), and Pfizer Global Research and Development, Sandwich (E.V.D.R., I.K., M.W., J.F.S., C.R., S.F.) — both in the United Kingdom; Istituto di Ricerca e Cura a Carattere Scientifico San Raffaele, Milan, Italy (A.L.); University Medical Center Utrecht, Utrecht, the Netherlands (A.I.M.H.); University of California, San Francisco, and San Francisco Veterans Affairs Medical Center — both in San Francisco (H.L.); Geneva University Hospital, Geneva (B.H.); University of Pennsylvania, Philadelphia (P.T.); University Hospital, Hôtel-Dieu, Medical University, Nantes, France (F.R.); Clinique Médicale L'Actuel, Montreal (B.T.); Southwest Infectious Disease Associates, Dallas (N.B.); University of Alabama, Birmingham, Birmingham (M.S.); Pfizer Global Research and Development, New London, CT (M.T., M.W.D., H.M.); and National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney (D.A.C.).
Address reprint requests to Dr. Fätkenheuer at the Universitätsklinik Köln, 50924 Köln, Cologne, Germany, or at g.faetkenheuer{at}uni-koeln.de.
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
Previous
